The Rising Role Of SNP Genotyping In Chronic Disease Management: Strategic Insights Driving Single Nucleotide Polymorphism (SNP) Genotyping Market Momentum in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Single Nucleotide Polymorphism (SNP) Genotyping Market Size By 2025?
The market dealing with single nucleotide polymorphism (snp) genotyping has experienced substantial expansion recently; projections indicate a rise from a valuation of $10.3 billion in 2024 to $12.34 billion in 2025, reflecting a robust compound annual growth rate (CAGR) reaching 19.8%. This historical ascent is largely credited to heightened genomic investigations, a surge in the prevalence of genetic conditions, the expansion of tailored medical approaches, the growth within the pharmaceutical sector, and escalating requirements for molecular analysis tools.

How Big Is the Single Nucleotide Polymorphism (SNP) Genotyping Market Size Expected to Grow by 2029?
Anticipation surrounds the single nucleotide polymorphism genotyping market, projecting substantial expansion in the immediate future, with its valuation projected to reach $24.89 billion by 2029, reflecting a compound annual growth rate (CAGR) of 19.2%; this upswing is fundamentally driven by the increasing utilization of genotyping in disease investigation, the escalating requirement for personalized medical approaches, the proliferation of biobanking endeavors, the heightened frequency of genetic screening, and greater incorporation within the agricultural sector for enhancing crop yields. Key developments shaping this market outlook include a marked inclination towards next-generation sequencing (NGS) technologies, burgeoning requirements for SNP analysis within pharmacogenomics, the growth trajectory of consumer-initiated genetic testing services, intensified concentration on automated processes, and the adoption of platforms capable of high-throughput genotyping.

View the full report here:
https://www.thebusinessresearchcompany.com/report/single-nucleotide-polymorphism-snp-genotyping-global-market-report

Which Key Market Drivers Powering Single Nucleotide Polymorphism (SNP) Genotyping Market Expansion and Growth?
The escalating prevalence of long-lasting ailments, defined as conditions persisting for a year or more that require ongoing medical attention, limit daily functions, or both, is projected to fuel the expansion of the market for single nucleotide polymorphism (SNP) genotyping moving ahead. Given the heightened incidence of persistent health issues, SNP genotyping stands as a critical tool for pinpointing genetic vulnerabilities and facilitating tailored medical approaches; for example, data released in June 2024 by the Australian Institute of Health and Welfare, an Australian governmental body, showed that the mortality rate associated with chronic diseases climbed from 459 fatalities per 100,000 individuals in 2021 to reach 490 fatalities per 100,000 individuals by 2022, thus, this growing weight from chronic diseases acts as a significant impetus for the market's development in single nucleotide polymorphism (SNP) genotyping solutions.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12569&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Single Nucleotide Polymorphism (SNP) Genotyping Market?
A significant movement characterizing the single nucleotide polymorphism (SNP) genotyping arena involves the adoption of cutting-edge technological products, with leading entities in this sector actively rolling out sophisticated advancements to solidify their standing. As an illustration of this trend, in May of 2022, Neogen Corporation, an American firm specializing in food safety provisions for sectors like agriculture, animal protein, food, and beverages, collaborated with Gencove, another US-based specialist in sequencing services, to unveil InfiniSEEK, which is recognized as the inaugural comprehensive genome and genotyping instrument tailored for bovine breeders; extensive verification processes have demonstrated that InfiniSEEK's low-pass genome-wide sequencing exhibits an agreement exceeding 99 percent when contrasted with deep whole-genome sequencing, and in specific important sections, it is capable of achieving superior accuracy comparable to clinical-grade standards.

What Are the Emerging Segments in the Single Nucleotide Polymorphism (SNP) Genotyping Market?
The single nucleotide polymorphism (snp) genotypingmarket covered in this report is segmented -

1) By Product: Consumables; Instruments; Services
2) By Technology: TaqMan SNP Genotyping; Mass Array SNP Genotyping; SNP Gene Chip Arrays; Other Technologies
3) By Application: Animal Genetics; Plant Improvement; Diagnostic Research; Pharmaceuticals And Pharmacogenomics; Agricultural Biotechnology; Other Applications

Subsegments:
1) By Consumables: Reagents And Kits; DNA Probes; Microarrays
2) By Instruments: SNP Genotyping Platforms; Sequencers; PCR Machines
3) By Services: SNP Genotyping Services; Data Analysis Services; Consultation Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12569&type=smp

Who Are the Global Leaders in the Single Nucleotide Polymorphism (SNP) Genotyping Market?
Major companies operating in the single nucleotide polymorphism (SNP) genotyping market include Thermo Fischer Scientific Inc., Danaher Corporation, Roche Diagnostics Corporation, GE HealthCare Technologies Inc., Eurofins Genomics LLC, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Sigma-Aldrich Corporation, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Promega Corporation, GenScript Biotech Corporation, Integrated DNA Technologies Inc., LGC Ltd., Sequenom Inc., Fluidigm Corporation, Agendia Inc., Nugen Technologies Inc., BioChain Institute Inc., Standard BioTools Inc., Oxford Gene Technology, Affymetrix Inc., PREMIER Biosoft International Inc., GenoLogics, Rubicon Genomics Inc., Xcelris Genomics, Douglas Scientific LLC, Golden Helix Inc.

Which are the Top Profitable Regional Markets for the Single Nucleotide Polymorphism (SNP) Genotyping Industry?
North America was the largest region in the single nucleotide polymorphism (SNP) genotyping market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single nucleotide polymorphism (SNP) genotyping market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12569

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.